Atara Biotherapeutics
OverviewSuggest Edit
Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Atara operates through the business of developing and commercializing therapeutics segment.
| Type | Public | |
| Founded | 2012 | |
| HQ | South San Francisco, CA, US | Map |
| Website | atarabio.com | |
| Employee Ratings | More | |
| Overall Culture | F | More |
Recent NewsAll News
- Thinking about buying stock in Clovis Oncology, Ashford Hospitality Trust, Atara Biotherapeutics, Sorrento Therapeutics, or Vertex Energy?
- Thinking about buying stock in CleanSpark, Atara Biotherapeutics, FuelCell Energy, Sorrento Therapeutics, or Plug Power?
- Thinking about buying stock in Evofem Biosciences, Village Farms, Atara Biotherapeutics, Cronos Group, or American Airlines?
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
Key People/Management at Atara Biotherapeutics
Pascal Touchon
President and Chief Executive Officer, Director
Eric Dobmeier
Director
Roy D. Baynes
Director
Ron Renaud
Chairman of the Board
Jakob Dupont
EVP, Head of Global Research & Development
Matthew Fust
Director, Audit Committee Chair
Atara Biotherapeutics Office Locations
Atara Biotherapeutics has offices in South San Francisco, Aurora, New York, Thousand Oaks and in 1 other location
South San Francisco, CA, US (HQ)
Building 83, 611 Gateway Blvd #900
Aurora, CO, US
12635 E Montview Blvd #280
New York, NY, US
135 E 57th St 14th Floor
Thousand Oaks, CA, US
2430 Conejo Spectrum St
Zug, CH
Baarerstrasse 14
Atara Biotherapeutics Financials and Metrics
Atara Biotherapeutics Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (77.5m) |
EBIT (Q2, 2020) | (78.0m) |
Market capitalization (23-Feb-2021) | 1.4b |
Closing stock price (23-Feb-2021) | 16.8 |
Cash (30-Jun-2020) | 74.5m |
EV | 1.3b |
Atara Biotherapeutics's current market capitalization is $1.4 b.
Annual
Quarterly
| USD | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.7m | 3.5m | 3.6m | 4.1m | 5.8m | 6.5m | 7.1m | 8.6m | 9.6m | 11.1m | 14.0m | 19.2m | 16.9m | 19.2m | 23.3m | 19.0m | 17.0m | 16.4m |
R&D expense | 4.2m | 5.8m | 7.0m | 8.1m | 11.2m | 13.0m | 18.8m | 17.5m | 18.3m | 20.6m | 28.5m | 33.4m | 43.4m | 48.7m | 52.3m | 53.5m | 57.7m | 61.6m |
Operating expense total | 5.9m | 9.3m | 10.6m | 12.3m | 17.1m | 19.5m | 25.9m | 26.2m | 27.9m | 31.7m | 42.5m | 52.6m | 60.2m | 67.9m | 75.5m | 72.6m | 74.7m | 78.0m |
EBIT | (5.9m) | (9.3m) | (15.1m) | (12.3m) | (17.1m) | (19.5m) | (25.9m) | (26.2m) | (27.9m) | (31.7m) | (42.5m) | (52.6m) | (60.2m) | (67.9m) | (75.5m) | (72.6m) | (74.7m) | (78.0m) |
Annual
Quarterly
| USD | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 25.7m | 71.3m | 26.2m | 54.5m | 22.1m | 26.4m | 46.0m | 62.4m | 64.2m | 60.5m | 90.5m | 103.2m | 66.0m | 56.2m | 59.2m | 94.4m | 70.2m | 74.5m |
Prepaid Expenses | 323.0k | 3.0m | 5.6m | 6.0m | 5.1m | 4.1m | 3.9m | 4.5m | 5.4m | 5.8m | 6.1m | 7.9m | 8.2m | 13.1m | 10.8m | 10.3m | 14.4m | 11.1m |
Current Assets | 52.0m | 169.7m | 160.6m | 340.2m | 311.7m | 298.9m | 282.2m | 235.3m | 222.5m | 206.2m | 413.6m | 425.1m | 373.0m | 250.8m | 201.1m | 293.4m | 229.2m | 359.0m |
PP&E | 14.0k | 47.0k | 42.0k | 46.0k | 1.1m | 1.8m | 2.1m | 4.4m | 20.3m | 22.2m | 58.2m | 66.1m | 68.3m | 58.1m | 57.1m | 55.7m | 54.4m | 53.6m |
Annual
Quarterly
| USD | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (17.5m) | (9.2m) | (24.1m) | (36.0m) | (16.6m) | (35.4m) | (60.8m) | (25.7m) | (53.1m) | (84.2m) | (41.4m) | (92.3m) | (150.7m) | (66.3m) | (140.6m) | (212.5m) | (73.5m) | (151.0m) |
Depreciation and Amortization | 4.0k | 6.0k | 11.0k | 21.0k | 15.0k | 79.0k | 210.0k | 206.0k | 428.0k | 678.0k | 333.0k | 1.1m | 2.3m | 1.6m | 1.9m | 4.0m | ||
Accounts Payable | (37.0k) | 354.0k | 1.2m | 1.4m | 451.0k | 1.8m | 3.0m | (466.0k) | 253.0k | (1.0k) | (2.1m) | (207.0k) | 116.0k | 2.7m | 2.6m | 1.5m | (590.0k) | (2.9m) |
Cash From Operating Activities | (11.7m) | (6.6m) | (12.9m) | (25.8m) | (12.5m) | (23.3m) | (38.9m) | (22.0m) | (42.3m) | (62.6m) | (34.8m) | (74.3m) | (122.4m) | (70.2m) | (124.8m) | (176.9m) | (67.0m) | (123.7m) |
| USD | Q3, 2014 |
|---|---|
Financial Leverage | -2.4 x |
Atara Biotherapeutics Operating Metrics
| FY, 2016 | |
|---|---|
Phase I Trials Products | 3 |
Phase II Trials Products | 3 |
Phase III Trials Products | 1 |
Atara Biotherapeutics Cybersecurity Score
Atara Biotherapeutics Environment, Social & Governance (ESG) Ratings
Atara Biotherapeutics Online and Social Media Presence
1.3k Twitter followers
Atara Biotherapeutics has 1.3k Twitter Followers. The number of followers has increased 7.1% month over month and increased 15% quarter over quarter
Atara Biotherapeutics's Trends
Twitter Engagement Stats for @atarabio
312
Tweets
1.2k
Following
1.3k
Followers
14
Tweets last 30 days
11.4
Avg. likes per Tweet
100%
Tweets with engagement
Atara Biotherapeutics Company Culture
Overall Culture
F
43/100
CEO Rating
A+
90/100
Compensation
A+
100/100
Atara Biotherapeutics News and Updates
January 27, 2021
Thinking about buying stock in Clovis Oncology, Ashford Hospitality Trust, Atara Biotherapeutics, Sorrento Therapeutics, or Vertex Energy?
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, AHT, ATRA, SRNE, and VTNR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
September 11, 2020
Thinking about buying stock in CleanSpark, Atara Biotherapeutics, FuelCell Energy, Sorrento Therapeutics, or Plug Power?
NEW YORK, Sept. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSK, ATRA, FCEL, SRNE, and PLUG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...
May 26, 2020
Thinking about buying stock in Evofem Biosciences, Village Farms, Atara Biotherapeutics, Cronos Group, or American Airlines?
NEW YORK, May 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVFM, VFF, ATRA, CRON, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
February 27, 2020
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
Company to host conference call today at 8:00 a.m. EST Company to host conference call today at 8:00 a.m. EST
February 05, 2020
Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today named Kristin Yarema as Chief Comm…
December 09, 2019
Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
61 patients with diverse EBV-associated diseases, including 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® (tabelecleucel) EAP study
Atara Biotherapeutics Blogs
March 01, 2021
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
On track to complete the rolling tab-cel® BLA submission in Q3 2021 for patients with EBV+ PTLD through active and productive discussions with FDA
On track with ATA188 Phase 2 RCT (randomized controlled trial) enrollment in patients with progressive forms of MS, enabling an interim analysis in H1 20…
February 18, 2021
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021
Live Conference Call and Webcast at 4:30 p.m. EST
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious disea…
February 08, 2021
Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
First presentation of transcriptional data for tab-cel® demonstrates consistency of the product’s activation profile irrespective of donor and consistent enrichment of receptors targeting EBV-driven diseases
Atara partnered with CareDx on an innovative testing solution that enables detection an…
January 19, 2021
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and…
January 10, 2021
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference
Atara achieved significant progress across its three strategic priorities in 2020
Atara is well-positioned for success in anticipated tab-cel® regulatory submissions, approval and launch
Atara has had productive interactions with the FDA for ATA188 and is progressing the Phase 2 randomized clin…
January 06, 2021
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers an…
Atara Biotherapeutics Frequently Asked Questions
When was Atara Biotherapeutics founded?
Atara Biotherapeutics was founded in 2012.
Who are Atara Biotherapeutics key executives?
Atara Biotherapeutics's key executives are Pascal Touchon, Eric Dobmeier and Roy D. Baynes.
How many employees does Atara Biotherapeutics have?
Atara Biotherapeutics has 393 employees.
Who are Atara Biotherapeutics competitors?
Competitors of Atara Biotherapeutics include Praxis Precision Medicines, Resolve Therapeutics and Felix Biotechnology.
Where is Atara Biotherapeutics headquarters?
Atara Biotherapeutics headquarters is located at Building 83, 611 Gateway Blvd #900, South San Francisco.
Where are Atara Biotherapeutics offices?
Atara Biotherapeutics has offices in South San Francisco, Aurora, New York, Thousand Oaks and in 1 other location.
How many offices does Atara Biotherapeutics have?
Atara Biotherapeutics has 5 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies